NASDAQ:BDSX
Biodesix Inc.
Biodesix Inc.'s revenue grew 24.1% in fiscal 2025 to $88.5M while operating margin rose to −31.5%, its highest in 7 years. Free cash flow was −$23.5M, −26.6% of revenue, and the diluted share count rose 16.7%.Summary generated from Biodesix Inc.'s SEC filings. Latest annual report filed Feb 26, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$88.5M
Revenue growth+24.1%
Revenue, 5-yr CAGR+14.2%
Gross marginn/a
Operating margin−31.5%
Net margin−39.8%
ROIC−69.7%
Return on equity−383.1%
Debt / equityn/a
Free cash flow−$23.5M
FCF margin−26.6%
Share count change+16.7%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 55 | 38 | 49 | 71 | 88 |
| Operating income | −41 | −51 | −41 | −34 | −28 |
| Net income | −43 | −65 | −52 | −43 | −35 |
| Free cash flow | −30 | −48 | −46 | −52 | −24 |
Recent filings
- 4Insider transaction report
Oct 2, 2026 - 4Insider transaction report
Aug 13, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 5, 2026 - 8-KResults of operations and financial condition
Aug 5, 2026 - 8-KResults of a shareholder vote
May 20, 2026 - 10-QQuarterly report for the period ended Mar 31, 2026
May 4, 2026 - 8-KResults of operations and financial condition
May 4, 2026 - DEF 14AProxy statement
Apr 9, 2026